50 results about "Treatment interval" patented technology

A system for treating a septal defect having an implantable treatment apparatus and devices for delivering the implantable treatment apparatus and methods for treating a septal defect are provided. The implantable treatment apparatus is preferably implantable through a septal wall or portion thereof. The treatment system can include a flexible elongate body member, a delivery device configured to deliver the implantable apparatus, a stabilization device configured to stabilize the body member and a positioning device configured to position the delivery device in a desired location.

Systems and methods for treating internal tissue defects, such as septal defects, with clip-based devices are provided. An exemplary clip-based device includes a tubular body having at least a first and a second deflectable member coupled thereto. The first and second members are coupled on opposite ends of the tubular body and configured to deflect between an undeployed configuration and a deployed configuration. In the deployed configuration, each member extends outwardly away from the tubular body in a position configured to abut a tissue surface. The first and second members are preferably configured to maintain a tissue wall therebetween and at least partially close any opening in the tissue wall.

The invention relates to a method for treating subterranean formation comprising providing distributed temperature sensors, injecting a treatment fluid and monitoring the temperature across the treatment interval during the injection process.

Baroreflex activation is achieved by providing suitable control signals to a baroreflex activation device. A method comprises establishing a therapy interval (possibly on the order of minutes to hours, or possibly of indefinite duration), within the therapy interval, establishing a plurality of dose intervals, and generating an electrical output signal. The electrical output signal has a time dependence such that the average electrical power applied to the baroreflex activation device differs between first and second portions of at least some dose intervals. Another method comprises establishing a series of therapy interval portions, during at least some therapy intervals, establishing a plurality of burst intervals (perhaps having durations commensurate with an interval between heartbeats), and generating an electrical output signal. The electrical output signal has a time dependence such that the average electrical power applied to the baroreflex activation device differs between first and second portions of the therapy intervals and also differs between first and second portions of at least some burst intervals.

An apparatus (50) for monitoring a treatment process in a treatment interval (58) includes a packer assembly (60) and a sand control screen assembly (64) connected relative to the packer assembly (60). A cross-over assembly (62) provides lateral communication paths (92, 98) downhole and uphole of the packer assembly for respectively delivering of a treatment fluid (84) and taking return fluid. A wash pipe assembly (76) is positioned in communication with the lateral communication path (98) uphole of the packer assembly (60) and extending into the interior of the sand control screen assembly (64). At least one sensor (80) is operably associated with the wash pipe assembly (76) to collect data relative to at least one property of the treatment fluid during a treatment process such that a characteristic of the treatment fluid (84) is regulatable during the treatment process based upon the data.

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

Apparatuses and methods support multi-modal operation of a medical device system for a nervous system disorder. The medical device system comprises an implanted component and an external component and supports a first feature and a second feature that are associated with the treatment therapy. The medical device system supports both features when the implanted component and the external component are coupled. If the external component is decoupled, the implanted component continues to support the first feature. Moreover, the embodiment may support a plurality of features during a treatment interval. Another aspect of the invention allows for modularly expanding a medical device system in order to add a feature that enhances existing functionality or that provides additional functionality. In an embodiment, a module that is associated with an external component of the medical device system supports the added feature.

The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets. The method of treatment is performed and then, depending upon the desired clinical outcome, repeated after a treatment response interval has elapsed.

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.

The invention discloses a treatment prompting method based on a network treatment platform. The method comprises: matching corresponding department and doctor according to registration information of a user; generating a treatment number corresponding to the doctor for the user and acquiring waiting information of the doctor, wherein the waiting information comprises a treatment queuing number of patients and a current treatment number; and when the interval between the treatment number of the patient and the current treatment number reaches a pre-set treatment interval, sending prompting information to the user to remind the user to enter a waiting room. The invention further discloses the network hospital platform. According to the scheme disclosed by the invention, the waiting prompt is pertinently sent to the user through the network hospital platform and the user can conveniently check the waiting information of a consulting room queued by the user, so that the user experience of the treatment prompt is enhanced.

Systems and methods for treating vertebral compression fractures are provided. A kit can include at least one body containing a bone cement precursor to be mixed with at least one other bone cement precursor to form a bone cement. The body or a package containing the body can include at least one sensor. In some embodiments the sensor can be a temperature sensor. In some methods, data from the sensor can be used to determine certain parameters related to a treatment interval involving the bone cement.

Methods, systems and devices for endometrial ablation. In accordance with a method, a working end of an RF ablation device is positioned in a patient uterus to contact endometrial tissue, the working end comprising a dielectric. Radiofrequency energy is applied for a first interval of time at constant power, the power being sufficient to capacitively couple current across the dielectric to the contacted endometrial tissue. A voltage parameter measured within the first interval, and radiofrequency energy is applied at a constant voltage over a second, treatment interval to ablate endometrial tissue, the constant voltage being related to the recorded voltage.

An X-ray machine for monitoring thermal treatment of human tissue produces a reference exposure of the tissue to be treated prior to commencement of the treatment. Thermal treatment is performed subsequently. Check exposures are made with the X-ray machine during the treatment or also during treatment intervals. The check exposures are performed as partial volume exposures at a lower radiation load than the reference exposures. From a comparison of check exposures with the reference exposures, conclusions can be drawn concerning changes of tissue temperature and also tissue properties.

Methods comprising: introducing a micro-proppant treatment fluid into a formation at a rate and pressure sufficient to create or enhance at least one fracture in a first treatment interval, wherein the micro-proppant treatment fluid comprises a first aqueous base fluid, micro-proppant particulates, and a first aqueous-based surface modification agent (“ASMA”); placing the micro-proppant particulates into the at least one fracture; introducing a surface modification treatment fluid into the subterranean formation, wherein the surface modification treatment fluid comprises a second aqueous base fluid and a second ASMA; coating at least a portion of a face of the at least one fracture with the second ASMA; introducing a macro-proppant treatment fluid into the subterranean formation, wherein the macro-proppant treatment fluid comprises a third base fluid and macro-proppant particulates; and placing the macro-proppant particulates into the at least one fracture.

The invention discloses a novel isoflavones compound as shown by a formula I. The results of animal experiments show that the isoflavones compound can significantly inhibit the proliferation of T cells and B cells, and can be used for preparing immunosuppressants or medicaments for treating immunologic diseases. The SI values (IC50/CC50) of the isoflavones compound are high, so the toxic side effects of the isoflavones compound are small, and the treatment interval of the isoflavones compound is wide. The isoflavones compound is obtained by extracting and separating clovershrubs, and the preparation method is simple and convenient.

A new and useful portable remote unattended low level light therapy (“LLLT”) orthopedic device that is lightweight, programmable, portable, affordable, able to be worn passively by the patient, able to operate unattended by a practitioner or physician, and can be used to administer multiple and/or extended treatment intervals outside the office setting. The device comprises a light therapy circuit with a power supply, controller circuit, LED driver circuit and an array of near infrared LEDs. Additionally the device comprises mode indicators and a program receiving port for programming by an external programming means. The entirety of the electrical components of the device are enclosed in a circuit housing and attached to a wearing means or brace. En toto, the device is used to direct low level light towards an indicated part of a patients anatomy in the field or orthopedic therapy.

The invention provides a community diagnosis and treatment reservation service system, which is characterized by comprising at least one site terminal and a center management device. A patient information storage part is used to store patient information of patients and corresponding disease types. An interval storage part stores multiple disease types and corresponding diagnosis and treatment intervals. A reservation control part controls a retrieval and acquisition part to retrieve the patient information storage part according to the received patient information to acquire a disease type ofthe corresponding patient and retrieve the interval storage part to acquire a corresponding diagnosis and treatment interval according to the disease type, controls a consultation time calculation part to calculate a next needed consultation date of the patient based on the diagnosis and treatment interval and the current date, controls the retrieval and acquisition part to retrieve a reservationrecord storage part according to the needed consultation date to acquire a reservation record of a doctor in the needed consultation date and further controls a center-side communication part to senda retrieved reservation record to the site terminal, and thus, the doctor selects a reservation time period.

A method and system directs therapeutic light of a first wavelength to a patient's eye to excite a photosensitizing agent for PDT during a series of discrete periods of time that are separated by non-therapeutic intervals. Diagnostic light of a second wavelength can be directed to the eye during at least a portion of one or more of the non-therapeutic intervals to allow a physician to see the affect of the therapy.